World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
66
Citations
24607
World Ranking
8466
National Ranking
211

Clare L. Scott publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Clare L. Scott sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 235 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Clare L. Scott D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Clare L. Scott sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 66 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Research.com Recognitions

  • 2017 - Fellow of the Australian Academy of Health and Medical Science

Overview

Clare L. Scott is affiliated with the Walter and Eliza Hall Institute of Medical Research in Australia. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on subfields including Oncology, Molecular Biology, Reproductive Medicine, Genetics, and Cancer Research.

The scientist's work addresses several main topics, such as ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, DNA repair mechanisms, BRCA gene mutations in cancer, CRISPR and genetic engineering, cancer genomics and diagnostics, and treatments for endometrial and cervical cancer.

Among recent publications, notable papers include:

  • Sequence and comparative analysis of the chicken genome provide unique perspectives on vertebrate evolution (2021), published in Kent Academic Repository (University of Kent)
  • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer (2020), published in Annals of Oncology
  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial (2021), published in The Lancet Oncology
  • CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer (2020), published in Nature Communications
  • Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) (2021), published in Nature Communications

Frequent co-authors throughout the scientist's career include Jonathan A. Ledermann, Matthew J. Wakefield, Chunxue Bai, Joseph Bauer, and Eric Bernicker.

Publications have appeared predominantly in venues such as Cancer, Journal of Clinical Oncology, bioRxiv (Cold Spring Harbor Laboratory), Clinical Cancer Research, and Cancer Research.

In recognition of their contributions, Clare L. Scott was named a Fellow of the Australian Academy of Health and Medical Science in 2017.

Best Publications

  • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

    Mark F. van Delft;Andrew H. Wei;Kylie D. Mason;Kylie D. Mason;Cassandra J. Vandenberg

  • Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer

    David D. Bowtell;David D. Bowtell;Steffen Böhm;Ahmed A. Ahmed;Paul Joseph Aspuria

  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Elizabeth M Swisher;Kevin K Lin;Amit M Oza;Clare L Scott

  • SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine

    Warren S Alexander;Robyn Starr;Robyn Starr;Jennifer E Fenner;Clare L Scott;Clare L Scott

  • Dominant Negative ATM Mutations in Breast Cancer Families

    Georgia Chenevix-Trench;Amanda B. Spurdle;Magtouf Gatei;Helena Kelly

  • Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

    Clare L. Scott;Elizabeth M. Swisher;Scott H. Kaufmann

  • Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

    Olga Kondrashova;Olga Kondrashova;Minh Nguyen;Kristy Shield-Artin;Kristy Shield-Artin;Anna V Tinker

  • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

    R.E. Miller;R.E. Miller;A. Leary;C.L. Scott;C.L. Scott;V. Serra

  • BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    Kevin K. Lin;Maria I. Harrell;Amit M. Oza;Ana Oaknin

  • p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

    Liz J. Valente;Daniel H.D. Gray;Daniel H.D. Gray;Ewa M. Michalak;Ewa M. Michalak;Josefina Pinon-Hofbauer

  • DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa.

    Jeffrey B. Kerr;Karla J. Hutt;Karla J. Hutt;Ewa M. Michalak;Ewa M. Michalak;Michele Cook

  • Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

    Ralph K Lindemann;Andrea Newbold;K F Whitecross;Leonie A Cluse

  • Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

    Mark S. Cragg;Claire Harris;Claire Harris;Andreas Strasser;Clare L. Scott;Clare L. Scott

  • Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

    Mark S. Cragg;Elisa S. Jansen;Michele Cook;Claire Harris

  • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

    Olga Kondrashova;Olga Kondrashova;Monique Topp;Monique Topp;Ksenija Nesic;Ksenija Nesic;Elizabeth Lieschke

  • Role of the chromobox protein CBX7 in lymphomagenesis

    Clare L. Scott;Jésus Gil;Eva Hernando;Julie Teruya-Feldstein

  • Genetic Influences Determining Progenitor Cell Mobilization and Leukocytosis Induced by Granulocyte Colony-Stimulating Factor

    Andrew W. Roberts;Simon Foote;Warren S. Alexander;Clare Scott

Frequent Co-Authors

David D.L. Bowtell
David D.L. Bowtell Peter MacCallum Cancer Centre
Andreas Strasser
Andreas Strasser Walter and Eliza Hall Institute of Medical Research
Elizabeth M. Swisher
Elizabeth M. Swisher University of Washington
Michael Friedlander
Michael Friedlander University of New South Wales
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
Stephen B. Fox
Stephen B. Fox Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry can open doors to a variety of rewarding careers and further studies within health and science fields. Many students are now considering flexible online programs that build on foundational biological sciences while providing direct career opportunities.

For those interested in pharmaceuticals, pharm d online programs offer advanced training for aspiring pharmacists. If health, fitness, or sports medicine appeal to you, earning an online bachelor's degree in exercise science or an online bachelor's in kinesiology can lead to roles in athletic training, rehabilitation, or wellness coaching.

More specialized options, like the shortest pmhnp program, prepare graduates for in-demand mental health nursing positions with a focus on efficiency and flexibility. No matter your career goals, online degrees related to biology and biochemistry offer pathways that combine convenience, depth, and excellent job prospects across healthcare and research industries.

Best Scientists Citing Clare L. Scott

Trending Scientists

Recently Published Articles